
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2022

Commission File Number: 001-40277

OLINK HOLDING AB (PUBL)
(Exact Name of Registrant as Specified in its Charter)

Uppsala Science Park
SE-751 83
Uppsala, Sweden
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On January 4, 2022, Olink Holding AB (publ) issued a news release, which is furnished as Exhibit 99.1 to this Form 6-K.

Exhibit No.	Description
--------------------	--------------------

99.1	Olink Holding AB (publ) news release dated January 4, 2022.
------	---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OLINK HOLDING AB (PUBL)

By: /s/ Jon Heimer

Name: Jon Heimer

Title: Chief Executive Officer

Date: January 4, 2022

Olink to present at the 40th Annual J.P. Morgan Healthcare Conference

UPPSALA, Sweden, January 4, 2022 -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced it will be virtually participating in the 40th Annual J.P. Morgan Healthcare Conference.

Jon Heimer, CEO, is scheduled to present on Wednesday, January 12th, 2022, at 9:00 am ET.

A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at <https://investors.olink.com/investor-relations>.

About Olink

Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

For more information please contact:

IR Contact

Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media Contact

Andrea Prander
Corporate Communications Manager
Mobile: + 46 768 775 275
andrea.prander@olink.com